Last reviewed · How we verify

Erleada — Competitive Intelligence Brief

Erleada (apalutamide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Oncology.

marketed Androgen receptor Oncology Live · refreshed every 30 min

Target snapshot

Erleada (apalutamide) — Johnson & Johnson. Erleada blocks the androgen receptor, a protein that helps cancer cells grow.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Erleada TARGET apalutamide Johnson & Johnson marketed Androgen receptor 2018-01-01
Talazoparib with enzalutamide talazoparib-with-enzalutamide Pfizer marketed PARP inhibitor and androgen receptor inhibitor PARP enzymes and androgen receptor Not yet launched
Winlevi CLASCOTERONE Sun Pharma marketed Androgen Receptor Inhibitor [EPC] Androgen receptor 2020-01-01
Nubeqa darolutamide Bayer marketed androgen receptor (AR) 2019-01-01
APALUTAMIDE APALUTAMIDE marketed Androgen Receptor (AR) 2018-01-01
Aveed TESTOSTERONE UNDECANOATE Marius marketed Androgen Androgen receptor 2014-01-01
Xtandi xtandi Astellas Pharma marketed Androgen receptor inhibitor Androgen receptor 2012-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Erleada — Competitive Intelligence Brief. https://druglandscape.com/ci/apalutamide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: